|Last Update: 05/22/13 - 4:00 PM EDT|
|YTD Performance: 57.39%|
|Previous Close: $123.50|
|52 Week Range: $58.53 - $131.82|
|Oustanding Shares: 417,122,477|
|Market Cap: 51,514,625,910|
|Qtr (06/13)||Qtr (09/13)||FY (12/13)||FY (12/14)|
|Number of Analysts||4||4||4||4|
|Growth Rate (Year over Year)||16.74%||8.61%||18.61%||21.73%|
These two names have been earnings leaders, and well worth putting on your watch list.
Shares of CELG downgraded to Perform from Outperform, Oppenheimer said. Concerns about future acquisitions.
CELG was downgraded from Overweight to Neutral, Piper Jaffray said. $86 price target. Company lacks near-term catalysts.
Shares of CELG now seen reaching $91, Jefferies said. Positive topline data for Abraxane. Buy rating.
CELG was downgraded from Buy to Neutral, UBS said. $80 price target. Valuation call, as the stock is up 27% since Revlimid was not approved in the EU.
Shares of CELG now seen reaching $90, according to BMO Capital. Revlimid patents should hold up well against generic challenges. Outperform rating.
Shares of CELG now seen reaching $81, Jefferies said. Estimates also raised on Myeloma survey. Buy rating.
Let's what's happened to the stock since reaching its newest low.
Dan Fitzpatrick examines three stocks viewed onFast Money. Today's stocks include Amgen, Gilead, and Celgene.
They remind me of the old-line pharma companies in their formative years.